In this issue:
Ixekizumab and sacroiliac joint structural lesions in axial SpA
Clinical subtype, sex and first-line bDMARD discontinuation in axial SpA
One-year results of bimekizumab in PsA
Subcutaneous abatacept for active idiopathic inflammatory myopathy
Sex differences in biologic and targeted synthetic DMARDs in RA
Biological and targeted synthetic DMARDs and incident chronic kidney disease
Multi-domain effectiveness of guselkumab in PsA
Prevalence and incidence of uveitis in patients with SpA
Effect of TNF-α inhibitors on risk of dementia
Long-term safety of bimekizumab in axial SpA or PsA
Please login below to download this issue (PDF)